ArticleMedComm2025

Efficacy, Safety, and Biomarkers of Neoadjuvant Dalpiciclib (CDK4/6 inhibitor) plus Aromatase Inhibitors in Operable HER2-Negative Luminal B Breast Cancer: A Prospective, Single-Center, Single-Arm, Phase II Trial (DANCER).

Yunxiang Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.